Nuveen Corporate Income 2023 Target Term Fund (JHAA)


Stock Price Forecast

Oct. 14, 2021


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Nuveen Corporate Income 2023 Target Term Fund chart...

About the Company

Nuveen Corporate Income 2023 Target Term Fund seeks to provide a high level of current income and return the original $9.875 net asset value per common share on or about 1 Dec 2023.* The Fund invests in a portfolio of primarily corporate debt securities, including bonds and senior loans. The Fund may invest in other types of securities including convertible securities and other types of debt instruments and derivatives that provide comparable economic exposure to the corporate debt market. Under normal circumstances, up to 30% of its managed assets may be in securities of non-U.S. issuers, including up to 20% of managed assets in emerging market issuers, and up to 10% of managed assets may be in non-U.S. dollar denominated securities. No more than 15% will be in securities rated CCC+/Caa1 or lower at the time of investment. In seeking to return the original NAV on or about 1 Dec 2023, the Fund intends to utilize various portfolio and cash flow management techniques, including setting aside a portion of its net investment income, possibly retaining gains, and limiting the longest maturity of any holding to no later than 1 Jun 2024.

$7B

Total Revenue

None

Employees

$598M

Market Capitalization

1.48

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $JHAA News

The Quality Closed-End Fund Report, March 2024

6h ago, source:

It is very possible to earn profitable returns in CEFs, when we put together a high-yielding CEF portfolio. Explore more ...

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

7d ago, source:

Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC)Based on early evidence of clinical ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...